Comment by biophysboy
2 days ago
How are we going to produce all of the basic research that is non-excludable & non-rival? What incentive do companies have to produce results like this?
The biotech industry is already tricky, with long lag times and a low probability of success. More risk just increases the discount rate and lowers the present value, making it an even less appealing investment.
Capital will seek the best opportunities, let's keep the incentive structure sane. Which means first tackling the biggest problems, with the highest probability of success, for the most people. As the opportunity space is explored or saturated, we'll move on to lower EROI opportunities. By getting the highest EROI initially we'l be richer still for chasing down philanthropic spaces (for the opportunities which do not make economic sense, but make moral, humanitarian sense)
Capital didn’t seek quantum mechanics which led to semi conductors which led to computers. Capital didn’t seek weather prediction which led to chaos theory which led to modern control systems for basically everything. And it certainly didn’t seek neural networks for the first half dozen decades they existed. So it seems like capital may have a poor nose for long term reach investment.
What capital seems to be doing right now is funding products that will create an AI replacement of my grandmother so I can continue to talk to her after she dies. Not exactly a good look.
"There will be so much money to go around for philanthropy" is also rich given that the world's richest man is going online to actively tell people not to give to the poor.
I ask again: How are we going to produce all of the basic research that is non-excludable & non-rival? What incentive do companies have to produce results like this?
Capital seeks the best opportunities, like deliberately lying about asbestos in baby powder, producing fraudulent research and continuing to profit off poisoning individuals.
Don't forget tobacco companies lying about cancer and oil and gas companies hiding climate change research.
7 replies →
This is unfair: biotech/pharma companies do valuable work, particularly in translational medicine.
[dead]